Geographic variation in the impact of novel melanoma therapies on mortality
Journal of the American Academy of Dermatology · 2026-08 · 95 (2) · 432-440
DOI: 10.1016/j.jaad.2026.03.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-08. Verfasst von Edward L Kong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts. Electronic address: edwardkong@hms.harvard.edu. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIGMS NIH HHS, National Institute on Aging.
Abstract (Originalsprache)
Background
Novel immunotherapies and targeted therapies have transformed melanoma treatment, but the geographic distribution of benefits remains unclear.
Objective
To quantify county-level variation in melanoma mortality declines following the introduction of novel therapies and identify associated patient and health system factors.
Methods
We conducted a repeated cross-sectional ecological study using county-level mortality data from the Surveillance, Epidemiology, and End Results (SEER) Program. The primary outcome was percent change in age-adjusted melanoma mortality between 2008–2013 and 2019–2023. County characteristics were obtained from the Area Health Resource File, American Hospital Association Survey, Medicare claims, and National Provider Identifier database. Associations were assessed using ordinary least squares regressions.
Results
National melanoma mortality declined 25.6% between 2008–2013 and 2019–2023. Across 751 counties, declines varied widely (median, 23.8%; interquartile range, 7.6%–35.6%). County population size was the strongest predictor of mortality decline (β = 4.5; 95% CI, 1.6–7.4; P = .002). Had all counties achieved the mortality reductions of the largest counties, 2,818 additional deaths could have been prevented.
Limitations
Ecological design and reliance on aggregates limit causal inference and individual-level interpretation.
Conclusions
Population size strongly predicts mortality benefits from novel melanoma therapies, underscoring the importance of strengthening health care infrastructure to reduce geographic disparities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Harvard Medical School, Boston, Massachusetts. Electronic address: edwardkong@hms.harvard.edu.
- Cutaneous Medical Oncology Program, Mass General Hospital Cancer Institute, Boston, Massachusetts.
- Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Förderung
- NIA NIH HHS
- NIGMS NIH HHS
- National Institute on Aging
Zitieren
APA
Kong, E. L., Sullivan, R., Tsao, H., & Chen, S. T. (2026). Geographic variation in the impact of novel melanoma therapies on mortality. Journal of the American Academy of Dermatology, 95(2), 432-440. https://doi.org/10.1016/j.jaad.2026.03.012
Vancouver
Kong EL, Sullivan R, Tsao H, Chen ST. Geographic variation in the impact of novel melanoma therapies on mortality. Journal of the American Academy of Dermatology. 2026;95(2):432-440. doi:10.1016/j.jaad.2026.03.012
BibTeX
@article{Kong2026,
author = {Kong, Edward L and Sullivan, Ryan and Tsao, Hensin and Chen, Steven T},
title = {Geographic variation in the impact of novel melanoma therapies on mortality},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
volume = {95},
number = {2},
pages = {432--440},
doi = {10.1016/j.jaad.2026.03.012}
}
EUVIMED